Literature DB >> 18332993

Major hepatectomy for isolated metastases from gastric adenocarcinoma.

Eduardo Linhares1, Mauro Monteiro, Rubens Kesley, Carlos Eduardo Santos, Odilon S Filho, Jose H Simões.   

Abstract

BACKGROUND: Liver metastases from gastric adenocarcinoma denote a poor prognosis. Most gastric metastases will be diffuse, and for these chemotherapy remains the only useful treatment modality. The treatment of isolated liver metastases is still unclear. The Japanese literature has reported good results with surgical resection, but Western series were unable to achieve the same results. We report our results with resection of liver metastases from gastric cancer in nine patients.
METHODS: A retrospective analysis was undertaken to determine the results of the surgical treatment of hepatic metastases from gastric carcinoma over the last five decades. Only nine patients underwent such treatment. Variables analysed were age, gender, the primary tumour, the type of liver operation performed, the time of occurrence of liver metastasis, the morbidity and mortality and the overall survival. Follow-up was complete.
RESULTS: There were eight patients with gastric carcinoma staged as T3 and one as T4 (UICC-97). All patients had positive lymph nodes. The hepatic procedure performed was a hemihepatectomy in eight patients and a left lateral segmentectomy in one patient. Right hepatectomy was performed in six cases. There were four patients with synchronous liver metastasis: three involved the right liver and the other involved segments II/III. All were treated by one-step surgery. The five metachronous metastases involved the right liver in three patients (accounting for half of the right hepatectomies), while the other two underwent left hepatectomies. There was a high postoperative mortality rate (33%, 3/9), two of the deaths occurring in the first decade of the study (1956, 1966) secondary to hepatic insufficiency and one from sepsis. One patient died suddenly without recurrence after 3 months. The other five died with evidence of disease at between 2 and 11 months. DISCUSSION: Despite some anecdotal reports of treatment with chemotherapy, either systemic or intrahepatic, the more consistent results for the treatment of patients with hepatic metastases from gastric adenocarcinoma come from the Japanese literature with the use of radical surgery. Unfortunately, Western series, including our own, do not achieve the same results. At the present time, in view of these results, we are performing less aggressive treatment such as radio-frequency ablation.

Entities:  

Year:  2003        PMID: 18332993      PMCID: PMC2020597          DOI: 10.1080/13651820310015815

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  11 in total

1.  Hepatic resection for metastatic tumors from gastric cancer.

Authors:  Keiichi Okano; Takashi Maeba; Ken Ishimura; Yukihiko Karasawa; Fuminori Goda; Hisao Wakabayashi; Hisashi Usuki; Hajime Maeta
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

2.  Factors influencing survival of patients undergoing hepatectomy for colorectal metastases.

Authors:  J Yamamoto; K Shimada; T Kosuge; S Yamasaki; M Sakamoto; H Fukuda
Journal:  Br J Surg       Date:  1999-03       Impact factor: 6.939

3.  Survival after liver resection for secondary tumors.

Authors:  J H Foster
Journal:  Am J Surg       Date:  1978-03       Impact factor: 2.565

4.  Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors.

Authors:  S D Bines; G England; D J Deziel; T R Witt; A Doolas; D L Roseman
Journal:  Surgery       Date:  1993-10       Impact factor: 3.982

5.  Hepatic resection for secondary neoplasms.

Authors:  C E Morrow; T B Grage; D E Sutherland; J S Najarian
Journal:  Surgery       Date:  1982-10       Impact factor: 3.982

6.  Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases.

Authors:  Y Yonemura; N Matuki; H Sakuma; K Katayama; T Sawa; T Fujimura; S Ohyama; K Miwa; I Miyazaki; M Tanaka
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

7.  Evaluation of treatment for gastric cancer with liver metastasis.

Authors:  K Okuyama; K Isono; I K Juan; S Onoda; T Ochiai; Y Yamamoto; Y Koide; H Satoh
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

8.  Surgical treatment for gastric carcinomas with concomitant hepatic metastasis.

Authors:  A Saito; D Korenaga; Y Sakaguchi; S Ohno; Y Ichiyoshi; K Sugimachi
Journal:  Hepatogastroenterology       Date:  1996 May-Jun

9.  Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors.

Authors:  T Ochiai; M Sasako; S Mizuno; T Kinoshita; T Takayama; T Kosuge; S Yamazaki; K Maruyama
Journal:  Br J Surg       Date:  1994-08       Impact factor: 6.939

10.  Resection of colorectal liver metastases.

Authors:  J Scheele; R Stang; A Altendorf-Hofmann; M Paul
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  3 in total

1.  Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile?

Authors:  Mattia Garancini; Fabio Uggeri; Luca Degrate; Luca Nespoli; Luca Gianotti; Angelo Nespoli; Franco Uggeri; Fabrizio Romano
Journal:  HPB (Oxford)       Date:  2012-03       Impact factor: 3.647

Review 2.  Surgical treatment of liver metastases of gastric cancer: state of the art.

Authors:  Fabrizio Romano; Mattia Garancini; Fabio Uggeri; Luca Degrate; Luca Nespoli; Luca Gianotti; Angelo Nespoli; Franco Uggeri
Journal:  World J Surg Oncol       Date:  2012-08-03       Impact factor: 2.754

3.  Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis.

Authors:  Sen-Feng Liu; Can-Rong Lu; Hai-Dong Cheng; Hong-Qing Xi; Jian-Xin Cui; Ji-Yang Li; Wei-Song Shen; Lin Chen
Journal:  Chin Med J (Engl)       Date:  2015-08-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.